UnknownPhase 1NCT03823365

Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

Studying Indolent B-cell non-Hodgkin lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
A.O. Ospedale Papa Giovanni XXIII
Principal Investigator
Alessandro Rambaldi, MD
ASST - Papa Giovanni XXIII
Intervention
Blinatumomab Expanded T-cells (BET)(biological)
Enrollment
19 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03823365 on ClinicalTrials.gov

Other trials for Indolent B-cell non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Indolent B-cell non-Hodgkin lymphoma →

← Back to all trials